Henry Schein

Henry Schein, Inc. engages in the provision of health care products and services to medical, dental, and veterinary office-based practitioners. It operates through the Healthcare Distribution, and Technology and Value-Added Services segments. The Healthcare Distribution segment includes consumable products, laboratory, small and large equipment repair services, branded and generic pharmaceuticals, vaccines, surgicals, diagnostic tests, infection-control products and vitamins. The Technology & Value-Added Services segment offers financial on a non-recourse basis, network and hardware services. The company was founded by Henry Schein and Esther Schein in 1932 and is headquartered in Melville, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Henry Schein reports solid Q4 performance and anticipates growth

Henry Schein's Q4 performance showcased growth amidst challenges, with a strategic focus on core margin expansion and strong performance in dental specialties. While facing challenges from declining PPE sales and supply chain issues, the company sees opportunities in stable dental markets and continued growth in operating income. Overall, the company remains optimistic about its outlook for 2023.

Henry Schein reports strong Q1 earnings, eyes growth through acquisitions

Henry Schein's Q1 2023 earnings call highlighted strong financial performance across its dental, medical, and Technology and Value-Added Services businesses. While facing challenges from declining PPE and COVID-19 test kit sales, the company remains optimistic about growth opportunities through acquisitions and stable business segments.

Henry Schein reports solid Q2 results, eyes growth opportunities

Henry Schein's Q2 performance was driven by strong dental sales, while facing challenges from declining PPE and COVID test kit sales. The company is focused on strategic acquisitions and expanding product offerings, with opportunities in technology and specialty products driving growth.

Henry Schein navigates post-cyber incident challenges, focuses on recovery

Henry Schein faced challenges from a cybersecurity incident impacting operations but showcased resilience and recovery efforts across its business segments.
Strategic initiatives focused on customer retention, operational efficiency, and cybersecurity response highlight the company's commitment to long-term growth and stability.
Despite challenges in specific segments and cybersecurity spending variables, Henry Schein's focus on recovery, cost-cutting, and customer trust positions it for future opportunities.
The company's emphasis on digital channels, stable medical demand, and strategic cost-cutting measures underscores its adaptability and strategic vision for sustained growth.

Henry Schein reports resilient Q4 performance and outlines 2024 guidance

Henry Schein's Q4 2023 performance reflects resilience amidst challenges, with a strategic focus on technology, global sales, and recovery post-cyber incident. The company's 2024 outlook includes managing residual cyber impacts and pursuing growth opportunities.

Henry Schein reports solid Q1 earnings, eyes market share expansion

Henry Schein's Q1 performance reflects resilience and growth across key segments, with a focus on market share expansion and profitability. While facing challenges in dental consumables and pricing stability, the company is leveraging opportunities in product portfolio expansion and market positioning. Strategic acquisitions and recovery efforts post-cyber incident are driving competitive strength and customer loyalty.

Henry Schein reports mixed Q2 performance, focuses on cost savings

Henry Schein navigated challenges from a cyber incident, with mixed performance across segments in Q2 2024.
Strong sales growth in dental specialties, focus on cost savings, and resilience in technology services were highlights.
The company's strategic initiatives, financial guidance update, and confidence in future prospects were key takeaways from the call.

Henry Schein excels in Q3 with strategic growth initiatives

Henry Schein's Q3 performance reflects strong market positioning and strategic execution, driving growth across key business segments.
While facing challenges such as LCI sales decline, the company's focus on operational efficiency and cost management remains a priority.
With increased sales guidance, ongoing restructuring initiatives, and strategic capital allocation plans, Henry Schein is poised for continued success and expansion.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Henry Schein, Inc. engages in the provision of health care products and services to medical, dental, and veterinary office-based practitioners. It operates through the Healthcare Distribution and Technology and Value-Added Services segments. The Healthcare Distribution segment includes consumable products, laboratory, small and large equipment repair services, branded and generic pharmaceuticals, vaccines, surgical, diagnostic tests, infection-control products, and vitamins. The Technology and Value-Added Services segment offers financial on a non-recourse basis, network, and hardware services. The company was founded by Henry Schein and Esther Schein in 1932 and is headquartered in Melville, NY.

Henry Schein's (HSIC) latest deal expands its offering in several fast-growing product segments, including clinical software and oral surgery and orthodontic products.

Henry Schein (HSIC) Expands Dental Offerings With New Pact

MELVILLE, N.Y.--( BUSINESS WIRE )--Henry Schein, Inc. (Nasdaq: HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, announced today that the Company will present at the following investor conferences:

Henry Schein to Present at Investor Conferences in January 2023

MELVILLE, N.Y.--( BUSINESS WIRE )--Henry Schein, Inc. (Nasdaq: HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, today announced a definitive agreement with the shareholders of Biotech Dental S.A.S., a rapidly growing provider of innovative clinical software and oral surgery and orthodontic products based in Salon-de-Provence, France, to acquire a majority ownership stake in the company.

Henry Schein Makes Investment to Form Strategic Partnership With Biotech Dental Group

MELVILLE, N.Y.--( BUSINESS WIRE )--Henry Schein, Inc. (Nasdaq: HSIC) and Team Schein Members (TSMs) from around the world are celebrating the Company's 24th annual “Holiday Cheer for Children” program, a flagship corporate initiative that helps underserved children and their families enjoy a fun and festive holiday season.

Henry Schein's 24th Annual ‘Holiday Cheer for Children' Helps Spread Joy Around the World

Henry Schein's (HSIC) recent deal with VideaHealth is expected to aid dentists in proving greater transparency to patients, thus making better treatment recommendations and improving case acceptance.

Henry Schein's (HSIC) New Tie-Up to Improve Patient Outcome

AMERICAN FORK, Utah--( BUSINESS WIRE )--Henry Schein One, a joint venture of Henry Schein, Inc. and Internet Brands, has accelerated its commitment to artificial intelligence (AI) and has announced a partnership with VideaHealth, a leading dental AI platform. As a result, Henry Schein One is introducing Dentrix® Detect AI powered and manufactured by VideaHealth, an AI-enabled X-Ray analysis tool that integrates directly into Dentrix® Practice Management Systems. The integration with VideaHealth's FDA-cleared computer-assisted detection (CADe) device can help oral health professionals harness the power of AI in dental practices.

Henry Schein One Partners With VideaHealth to Launch New Dentrix Detect AI X-Ray Analysis Tool to Enhance Patient Care

MELVILLE, N.Y.--( BUSINESS WIRE )--Henry Schein, Inc. (Nasdaq: HSIC) today announced its presence at the 2022 Greater New York Dental Meeting (GNYDM), featuring an expansive lineup of products and solutions designed to help oral health professionals enhance practice efficiency and the patient experience.

Henry Schein Announces Lineup of New Products, Software, and Equipment at the Greater New York Dental Meeting

Henry Schein's (HSIC) recent deal with Rimidi is expected to aid healthcare professionals in enhancing chronic disease management.

Henry Schein's (HSIC) New Deal to Improve Patient Outcome

MELVILLE, N.Y.--( BUSINESS WIRE )--Henry Schein, Inc. (Nasdaq: HSIC) and the American Association of Dental Office Management (AADOM) today announced that Jennifer Z. Vickery, Vice President of Operations, Oklahoma-based Ocean Dental, has been selected as the recipient of the ninth annual Green Leader Award. Ms. Vickery was presented with the award by Lorie Streeter, Vice President, AADOM, and Karen Golden Russell, Vice President and General Manager, Practice Services, Henry Schein Dental, at the recent 2022 AADOM Conference in Scottsdale, Arizona.

Henry Schein Cares Foundation and the American Association of Dental Office Management Present the Ninth Annual Green Leader Award to Ocean Dental's Jennifer Z. Vickery

Henry Schein, Inc. meets the need for continued growth projected into the future. Henry Schein's organic sales are robust across all regions and segments.

Henry Schein: Long-Term Value Selling Cheap, But Could Get More Attractive

NEW YORK--( BUSINESS WIRE )--Scott+Scott Attorneys at Law LLP (“Scott+Scott”), an international securities and consumer rights litigation firm, is investigating whether certain directors and officers of Henry Schein, Inc. (“Henry Schein”) (NASDAQ: HSIC) breached their fiduciary duties to Henry Schein and its shareholders. If you are a Henry Schein shareholder, you may contact attorney Joe Pettigrew for additional information toll-free at 844-818-6982 or jpettigrew@scott-scott.com.

INVESTIGATION ALERT: Scott+Scott Attorneys at Law LLP Investigates Henry Schein, Inc.'s Directors and Officers for Breach of Fiduciary Duties – HSIC

Henry Schein to Present at Upcoming Investor Conferences

Henry Schein, Inc. (NASDAQ:HSIC ) Q3 2022 Earnings Conference Call November 1, 2022 10:00 AM ET Company Participants Graham Stanley - VP of IR & Strategic Financial Project Officer Stanley Bergman - Executive Chairman & CEO Ron South - SVP & CFO Conference Call Participants Jeff Johnson - Baird Elizabeth Anderson - Evercore ISI Brandon Vazquez - William Blair A.J. Rice - Credit Suisse Jon Block - Stifel Erin Wright - Morgan Stanley Jason Bednar - Piper Sandler Operator Good morning, ladies and gentlemen, and welcome to Henry Schein's Third Quarter 2022 Earnings Conference Call.

Henry Schein, Inc. (HSIC) CEO Stanley Bergman on Q3 2022 Results - Earnings Call Transcript

Severe currency headwinds and lower sales of PPE and COVID-19 test kits affect Henry Schein's (HSIC) top line in Q3.

Henry Schein (HSIC) Q3 Earnings In Line, 2022 Sales View Down

Henry Schein (HSIC) delivered earnings and revenue surprises of 0.88% and 4.62%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Henry Schein (HSIC) Surpasses Q3 Earnings Estimates

Henry Schein Reports Record Non-GAAP Third-Quarter 2022 Diluted EPS Financial Results

We expect the Condor Dental buyout to have a beneficial impact on Henry Schein's (HSIC) results in the to-be-reported quarter.

Henry Schein (HSIC) to Report Q3 Earnings: What's in Store?

Henry Schein to Present at Investor Conferences in November

Henry Schein's Steven W. Kess Receives Presidential Citation From the American Dental Association

AMERICAN FORK, Utah--(BUSINESS WIRE)--Henry Schein One, a joint venture of Henry Schein, Inc. and Internet Brands, and Smile Brands today announced that Dentrix Ascend® cloud-based practice management software from Henry Schein One will be adopted as the exclusive dental practice management system of Smile Brands and its affiliated dental practices. Smile Brands, a 700-practice dental service organization (DSO) headquartered in Irvine, California, chose Dentrix Ascend because of its powerful cl

Dentrix Ascend Selected for Use as the Exclusive Practice Management System of Smile Brands

MELVILLE, N.Y.--(BUSINESS WIRE)--Henry Schein aids relief efforts from Florida and Puerto Rico up to Eastern Canada and opens the Company's disaster relief fund.

Henry Schein Aids Relief Efforts From Florida and Puerto Rico Up to Eastern Canada and Opens Disaster Relief Fund

MELVILLE, N.Y.--(BUSINESS WIRE)--Henry Schein, Inc. (Nasdaq: HSIC) announced today that it has been named to FORTUNE® magazine's "Change the World" list, an annual recognition of select companies that, through their work and initiatives, create positive social impact as part of their core business strategy. Henry Schein was recognized for its leadership initiatives designed to advance health equity for individuals with disabilities, and in particular, engaging the Company's key stakeholder rela

Henry Schein Named to Fortune® Magazine's ‘Change the World' List

MELVILLE, N.Y.--(BUSINESS WIRE)--Henry Schein to webcast third quarter 2022 conference call on Tuesday, November 1, 2022.

Henry Schein to Webcast Third Quarter 2022 Conference Call on Tuesday, November 1, 2022 at 10:00 A.M. ET

MELVILLE, N.Y.--(BUSINESS WIRE)--Henry Schein's Practice Pink Program Supports Organizations Dedicated to Cancer Research, Prevention, and Awareness

Henry Schein's Practice Pink Program Supports Organizations Dedicated to Cancer Research, Prevention, and Awareness

Becton, Dickinson and Co.

Public-Private Partnership Supporting Diagnostic Testing in Vulnerable Communities has Provided $2.6 Million to U.S. Clinics Since 2017 to Help Improve Patient Outcomes and Health Equity FRANKLIN LAKES, N.J. , Sept. 29, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, in conjunction with Heart to Heart International (HHI), the National Association of Free and Charitable Clinics (NAFC) and Henry Schein Cares, today announced that six U.S. free and charitable clinics will be awarded product-based grants worth a total of $360,000 to support point-of-care diagnostic testing in communities with underserved and at-risk patient populations.

News for Henry Schein Stock (HSIC)